[go: up one dir, main page]

AR096162A1 - Péptidos terapéuticos - Google Patents

Péptidos terapéuticos

Info

Publication number
AR096162A1
AR096162A1 ARP140101793A ARP140101793A AR096162A1 AR 096162 A1 AR096162 A1 AR 096162A1 AR P140101793 A ARP140101793 A AR P140101793A AR P140101793 A ARP140101793 A AR P140101793A AR 096162 A1 AR096162 A1 AR 096162A1
Authority
AR
Argentina
Prior art keywords
leu
lys
ala
pyy
ser
Prior art date
Application number
ARP140101793A
Other languages
English (en)
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR096162A1 publication Critical patent/AR096162A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

La presente solicitud se refiere a análogos de PYY (péptido de pliegue PP) que tienen un perfil terapéutico modificado cuando se comparan con el PYY humano nativo. Estos análogos de PYY son útiles en el tratamiento de obesidad, diabetes, y otros trastornos. Reivindicación 1: Un polipéptido que comprende la secuencia de aminoácidos: ProLysProGluXaa¹ProGlyXaa²AspAlaSerXaa³GluGluXaa⁴Xaa⁵Xaa⁶TyrTyrAlaXaa⁷LeuArgXaa⁸TyrXaa⁹AsnTrpXaa¹⁰ThrArgGlnArgTyr (SEQ ID Nº 1), o una sal del mismo, en donde: Xaa¹ es ala, His, o Ser; Xaa² es Glu o Lys; Xaa³ es Pro o Ala; Xaa⁴ es Leu o Trp; Xaa⁵ es Asn, Ala, o Thr; Xaa⁶ es Arg o Lys; Xaa⁷ es Ser, Asp, o Ala; Xaa⁸ es His o Lys; Xaa⁹ es Leu o Ile; y Xaa¹⁰ es Val o Leu.
ARP140101793A 2013-05-02 2014-04-30 Péptidos terapéuticos AR096162A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818624P 2013-05-02 2013-05-02

Publications (1)

Publication Number Publication Date
AR096162A1 true AR096162A1 (es) 2015-12-09

Family

ID=50842285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101793A AR096162A1 (es) 2013-05-02 2014-04-30 Péptidos terapéuticos

Country Status (20)

Country Link
US (2) US20160108098A1 (es)
EP (1) EP2992008B1 (es)
JP (1) JP2016519130A (es)
KR (1) KR20160003848A (es)
CN (1) CN105263957A (es)
AR (1) AR096162A1 (es)
AU (1) AU2014261111B2 (es)
BR (1) BR112015027528B1 (es)
CA (1) CA2909045C (es)
CL (1) CL2015003199A1 (es)
EA (1) EA201591839A1 (es)
ES (1) ES2732291T3 (es)
HK (1) HK1214829A1 (es)
MX (1) MX2015015249A (es)
PE (1) PE20151808A1 (es)
RU (1) RU2015144632A (es)
SG (1) SG11201508469YA (es)
TW (1) TW201534616A (es)
UY (1) UY35548A (es)
WO (1) WO2014178018A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
US20160108098A1 (en) * 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
CN107849110B (zh) 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
KR20180091098A (ko) * 2015-12-28 2018-08-14 이데미쓰 고산 가부시키가이샤 펩티드 태그 및 그것을 포함하는 태그 부가 단백질
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
JP2020510028A (ja) 2017-03-08 2020-04-02 インターシア セラピューティクス，インコーポレイティド 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TWI865836B (zh) 2018-11-01 2024-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
EP4069274A4 (en) * 2019-12-04 2024-04-10 The Scripps Research Institute PEPTIDE CONJUGATES AND METHODS OF USE
IL297368A (en) * 2020-04-17 2022-12-01 I2O Therapeutics Inc Long-acting peptide tyrosine kinase (pyy) analogs and methods of use
AU2021322137A1 (en) 2020-08-07 2023-01-19 Boehringer Ingelheim International Gmbh Soluble NPY2 receptor agonists
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2025217640A1 (en) * 2024-04-12 2025-10-16 Eli Lilly And Company Compositions and methods for treating metabolic diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
DE69838791T3 (de) 1997-08-08 2011-06-22 Amylin Pharmaceuticals, Inc., Calif. Neue exendinagonist verbindungen
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AU756836B2 (en) 1997-11-14 2003-01-23 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO2002013786A2 (en) 2000-08-15 2002-02-21 Board Of Trustees Of The University Of Illinois Method of forming microparticles
CN100350968C (zh) * 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2006066024A2 (en) 2004-12-13 2006-06-22 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
JP2008514616A (ja) * 2004-09-24 2008-05-08 メルク エンド カムパニー インコーポレーテッド 肥満の治療のための組合せ療法
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2009530407A (ja) * 2006-03-23 2009-08-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
WO2011050008A2 (en) 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
WO2012006566A2 (en) * 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
GB201101459D0 (en) * 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20160108098A1 (en) * 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途

Also Published As

Publication number Publication date
RU2015144632A (ru) 2017-06-07
BR112015027528A2 (pt) 2017-12-05
EP2992008B1 (en) 2019-04-10
TW201534616A (zh) 2015-09-16
CL2015003199A1 (es) 2016-05-06
US20160108098A1 (en) 2016-04-21
CA2909045C (en) 2022-12-06
KR20160003848A (ko) 2016-01-11
US9441023B2 (en) 2016-09-13
CN105263957A (zh) 2016-01-20
UY35548A (es) 2014-11-28
PE20151808A1 (es) 2015-12-16
AU2014261111B2 (en) 2017-03-16
MX2015015249A (es) 2016-02-09
CA2909045A1 (en) 2014-11-06
HK1214829A1 (zh) 2016-08-05
JP2016519130A (ja) 2016-06-30
WO2014178018A1 (en) 2014-11-06
EP2992008A1 (en) 2016-03-09
US20140329742A1 (en) 2014-11-06
EA201591839A1 (ru) 2016-05-31
BR112015027528B1 (pt) 2023-02-14
ES2732291T3 (es) 2019-11-21
SG11201508469YA (en) 2015-11-27
AU2014261111A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
AR096162A1 (es) Péptidos terapéuticos
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
MX2018014016A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
MX388822B (es) Composiciones que comprenden peptido wkdeagkplvk.
PE20121721A1 (es) Analogo peptidico de oxintomodulina
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
AR094180A1 (es) Derivados de exendina-4
PE20171058A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
EA201690494A1 (ru) Ацилированные аналоги глюкагона
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
PE20211466A1 (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta
EA201690606A1 (ru) Аналоги глюкагона
JP2011523935A5 (es)
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
AR107890A1 (es) Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
BR112013013548B8 (pt) Proteína de fusão anticancerígena
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2017502003A5 (es)
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
MX2016006049A (es) Mimeticos de calcitonina para tratar enfermedades y trastornos.
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
PE20200894A1 (es) Polipeptidos variantes del factor de crecimiento tipo insulina 1
CU24746B1 (es) Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7

Legal Events

Date Code Title Description
FB Suspension of granting procedure